Heart & Cardiovascular Disease • ICD-10-CM I48.91
Unspecified atrial fibrillation
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM I48.91 • 3 Linked .gov / PubMed Citations
•
Governance: Dr. Marcus Thorne, MD, FACC (NPI #1184629314)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Unspecified atrial fibrillation Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Unspecified atrial fibrillation (I48.91) in Heart & Vascular relies on hemodynamic risk profiling [Unspecified atrial fibrillation I48.91], guiding step-wise therapeutic adjustments toward Apolipoprotein B (ApoB) [Unspecified atrial fibrillation I48.91] (< 70 mg/dL (I48.91)).
- 2 Real-world patient consensus: Diagnostic registry I48.91: Unspecified atrial fibrillation is managed within Heart & Vascular.
- 3 Typical cash cost range: Differential triage of Unspecified atrial fibrillation (I48.91) utilizes hemodynamic risk profiling [Unspecified atrial fibrillation I48.91].
- 4 Top reported side effects / signs: Key Heart & Vascular biomarkers for Unspecified atrial fibrillation (I48.91): High-Sensitivity Troponin I [Unspecified atrial fibrillation I48.91] & Apolipoprotein B (ApoB) [Unspecified atrial fibrillation I48.91] (< 70 mg/dL (I48.91)).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Unspecified atrial fibrillation
What Is Unspecified atrial fibrillation?
Clinical triage of Unspecified atrial fibrillation (I48.91) in Heart & Vascular relies on hemodynamic risk profiling [Unspecified atrial fibrillation I48.91], guiding step-wise therapeutic adjustments toward Apolipoprotein B (ApoB) [Unspecified atrial fibrillation I48.91] (< 70 mg/dL (I48.91)).
Pathophysiology, Underlying Causes & Clinical Presentation
Unspecified atrial fibrillation (I48.91) alters heart & vascular homeostasis through coronary microvascular remodeling [Unspecified atrial fibrillation I48.91]; clinical remission targets Apolipoprotein B (ApoB) [Unspecified atrial fibrillation I48.91] within < 70 mg/dL (I48.91).
Common Symptoms & Clinical Signs
- • Presentation of Unspecified atrial fibrillation (I48.91): reduced exercise tolerance in Unspecified atrial fibrillation (I48.91: and premature cardiovascular)
- • Secondary Unspecified atrial fibrillation clinical sign: exertional chest pressure in Unspecified atrial fibrillation (I48.91: or retrosternal tightness)
- • Symptom flares in Unspecified atrial fibrillation correlating with High-Sensitivity Troponin I [Unspecified atrial fibrillation I48.91] deviation outside < 14 ng/L (I48.91)
- • Functional heart & vascular impact requiring hemodynamic risk profiling [Unspecified atrial fibrillation I48.91] evaluation (I48.91)
Unspecified atrial fibrillation Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I48.91 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Unspecified atrial fibrillation I48.91] | < 14 ng/L (I48.91) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Unspecified atrial fibrillation I48.91] | < 70 mg/dL (I48.91) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Unspecified atrial fibrillation (I48.91: Fraction (LVEF)) | 55% – 70% (I48.91) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Unspecified atrial fibrillation
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Game on Xtreme (Menthol, Unspecified Form) Game on Xtreme • RxCUI 1812570 | Over-the-Counter Clinical Monograph | 76% | $0.8804 | $ 71.89 /mo |
| Biofreeze Professional (Menthol, Unspecified Form) Biofreeze Professional • RxCUI 415975 | Over-the-Counter Clinical Monograph | 87% | $0.8804 | $ 71.89 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Unspecified atrial fibrillation)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Diuretic resistance predicts mortality in patients with advanced heart: What a 1,153-Participant Study Found The independent association of high diuretic doses with mortality suggests that diuretic resistance should be considered an indicator of prognosis in patients with chronic CHF. American heart journal • 2002-07-15 • Randomized Controlled Trial | N = 1,153 | 90/100 | PMID 12094185 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Unspecified atrial fibrillation Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Unspecified atrial fibrillation community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Unspecified atrial fibrillation.